Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNCP...IMO...tip of the iceberg
GNCP...Thanks! I received the exact same e-mail at 4:25 PM EST
GNCP...great e-mail clarification with Ron! Thanks for sharing!!
GNCP...IMO...BioCann Pharma SAS...along with Biominerals Pharma & BioCann Pharmaceuticals South Africa (SA) keep an eye on this one!
BioCann Sciences:
https://99designs.com/logo-design/contests/high-end-vitamin-supplements-brand-832976
Who are you known as?
BioCann Sciences
Tell us a bit about who you are and the people you reach
We provide high end quality hemp derived CBD products. The products provide a variety of medicinal benefits for people suffering from a variety of ailments.
What industry do you think your business is most related to?
Medical & Pharmaceutical
Other notes
We want to portray a high end brand. We like simplicity, clean and simple. Think biology, nutraceuticals, health and wellness, vitamins and supplements that enhance peoples well being, but a science driven company that provides products that get real results.
GNCP...indeed, BUT more adversely true than you can fathom. Keeping a gateway to those 1's? :D
GNCP...We've bumped up to #7 on the Breakout Board! Pink-Current! & News on all fronts...IMMINENT!! Many eyes watching and waiting!
GNCP..."OTC Markets update the FOLLOWING BUSINESS DAY" We're pink-current on Monday!!
GNCP...Comments from Ron
Sir,
OTC Markets Compliance formally approved the GNCP Financial Reports & Disclosure Statements an hour ago. This followed their review and our complying with their additional information requests.
GNCP...Let's go pink-current!!
GNCP...Comments from Ron (reposted without red font.)
Sir,
The Preferred Stock is NOT eligible to be converted for ONE YEAR from Issuance.
OBVIOUSLY no Preferred Stockholder is going to (or has) converted much stock as it would flood the market, increase the “float” and be highly prejudicial to their personal financial returns!
SERIES B:-
Each share of Series B Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after 1 (One) one year after the date such share was issued (subject to the limitations set forth in Section 6.c below), and without the payment of additional consideration by the holder thereof, into such number of fully-paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value per share, by the Series B Preferred Convertible Stock, Conversion Price in effect at the time of conversion.
The “Series B Conversion Price” shall be Fifty Percent (50%) of the average trading price for the 5 (Five) consecutive trading days next preceding the date of the notice of conversion as reported on OTCMarkets.com or such other United States trading market or stock exchange as shall then be the primary market (by volume) for the Corporation’s shares of common stock; provided, however, that the Series B Conversion Price, and the rate at which shares of Series B Convertible Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in Section 7 below. Shares of Series B Convertible Preferred Stock converted into shares of Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.
SERIES X:-
Each share of Series X Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after 1 (One) one year after the date such share was issued and without the payment of additional consideration by the holder thereof, into such number of fully-paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value per share, by the Series X Preferred Convertible Stock, Conversion Price in effect at the time of conversion.
The “Series X Conversion Price” shall be 85% (Eighty five percent) of the average trading price for the 5 (Five) consecutive trading days next preceding the date of the notice of conversion as reported on OTCMarkets.com or such other United States trading market or stock exchange as shall then be the primary market (by volume) for the Corporation’s shares of common stock; provided, however, that the Series X Conversion Price, and the rate at which shares of Series X Convertible Preferred Stock may be converted into shares of Common Stock. Shares of Series X Convertible Preferred Stock converted into shares of Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.
I hope this clarifies this for you. Please do not hesitate to contact me should you require further information.
GNCP...Comments from Ron
Sir,
The Preferred Stock is NOT eligible to be converted for ONE YEAR from Issuance.
OBVIOUSLY no Preferred Stockholder is going to (or has) converted much stock as it would flood the market, increase the “float” and be highly prejudicial to their personal financial returns!
SERIES B:-
Each share of Series B Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after 1 (One) one year after the date such share was issued (subject to the limitations set forth in Section 6.c below), and without the payment of additional consideration by the holder thereof, into such number of fully-paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value per share, by the Series B Preferred Convertible Stock, Conversion Price in effect at the time of conversion.
The “Series B Conversion Price” shall be Fifty Percent (50%) of the average trading price for the 5 (Five) consecutive trading days next preceding the date of the notice of conversion as reported on OTCMarkets.com or such other United States trading market or stock exchange as shall then be the primary market (by volume) for the Corporation’s shares of common stock; provided, however, that the Series B Conversion Price, and the rate at which shares of Series B Convertible Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in Section 7 below. Shares of Series B Convertible Preferred Stock converted into shares of Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.
SERIES X:-
Each share of Series X Convertible Preferred Stock shall be convertible, at the option of the holder thereof, at any time after 1 (One) one year after the date such share was issued and without the payment of additional consideration by the holder thereof, into such number of fully-paid and non-assessable shares of Common Stock as is determined by dividing the Stated Value per share, by the Series X Preferred Convertible Stock, Conversion Price in effect at the time of conversion.
The “Series X Conversion Price” shall be 85% (Eighty five percent) of the average trading price for the 5 (Five) consecutive trading days next preceding the date of the notice of conversion as reported on OTCMarkets.com or such other United States trading market or stock exchange as shall then be the primary market (by volume) for the Corporation’s shares of common stock; provided, however, that the Series X Conversion Price, and the rate at which shares of Series X Convertible Preferred Stock may be converted into shares of Common Stock. Shares of Series X Convertible Preferred Stock converted into shares of Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.
I hope this clarifies this for you. Please do not hesitate to contact me should you require further information.
GNCP...thanks TF & TFF for sharing updates.
GNCP...please save me!!!! (@ $1)
GNCP...by the way...
That quote from the GNCP/BioCann Pharma March 27, 2019 press release is nearly identical to the information posted on the former Instadose Pharma web page which discussed their future endeavors. Very interesting that GNCP/BioCann Pharma has adopted (or were instructed?) identical objectives after the joint venture with Instadose Pharma on March 1, 2019.
GNCP...future acquisitions are proposed to be CASH transactions as of March 27, 2019
https://www.marketwatch.com/press-release/gncc-capital-inc-updates-on-various-matters-2019-03-27?siteid=nbkh
The Company has elected to fairly aggressively add to its interests in the Cannabis and related Sectors. This will include outright purchases of companies, acquisition of minority interests, Joint Ventures, Licensing Agreements and Service provision.
We are particularly interested in value added products and services in both the Cannabis and Hemp Sectors. This includes products in the beauty, health, wellness, pets and the delivery of value added cannabis products direct to consumers. Retailers' shelf space for these products is expanding rapidly due to strong consumer interest and increasing market demand.
Hemp based products are an important area for our growth and we are seeking opportunities in that area. Naturally any such transactions will need to meet industry standards for quality and comply with all of the legal requirements for products containing hemp pursuant to the U.S. Farm Bill and other applicable regulations.
Two M & A Consultants have been retained to seek out suitable targets and to negotiate with the vendors of businesses currently being offered for sale and that meet our criteria; namely their being well established, profitable and cash flow positive. A number of targets have been identified in the USA and in Canada and negotiations are ongoing. The Company will be in a position to access certain amounts of CASH on an ongoing basis to facilitate the outright purchases of the companies targeted and for CASH.
The Consultants have indicated that they are reasonably confident that an initial four outright acquisitions could be consummated during next month.
We are exploring various options to acquire licensed retail operations with physical store locations and e-Commerce capabilities. This we would do gradually, if at all; due to the complexities of managing retail stores.
If successful in these acquisitions, we will be establishing an appropriate infrastructure in order to oversee and to properly manage all operational companies acquired, this to include a dedicated Management Team reporting to the Directors. We will then be in a position to commence with the provision and continual updating of guidance pertaining to our Revenues, Earnings per share, Trading conditions, etc.
All transactions will be effected through new wholly owned subsidiary companies of GNCC.
GNCP...Stay tuned for pink-current and acquisition(s) announcements!
GNCP..Comment from Ron
Sir,
I refer to you to SIGNED and filed Agreements,. This is bizarre. I will reach out to them now.
Ron Lowenthal
GNCP...also a sleeper cell. Appears and creates a Facebook coalition every time there is big news coming from GNCP. Beat it!!
GNCP...that article has been debunked several months ago. Fake news!
GNCP...Can you tell we're getting close? :)
GNCP...Update from Ron
Sir,
GNCC Capital, Inc. Counsel earlier indicated that the LATEST filing of his Attorneys Letter is now Wednesday, he had to include March 31, 2019 Quarterly filed yesterday; in his Report.
PLEASE remember that OTC Markets Compliance reviews these Quarterly and Annual Reports PRIOR to moving the Company to “CURRENT”.
Best we err on the side of caution in committing to specific dates.
GNCP...Take a look back to Ron's email from just May 4, 2019...15 filings complete, stop to yield to standing by for pink-current. Now focus on his last paragraph highlighted below in red font.
Sir,
You may rest assured that we are working non-stop to complete all of these Filings. I will NOT BE HELD TO DATES; and NO, that does NOT mean that we will miss our guided dates either.
We are ensuring that they are 100% accurate and that each one fully complies with all the new OTC Market requirements. Under no circumstances will we compromise on our extensive explanations, etc. as do so many other OTC Market quoted Companies.
Historically our Quarterly and Annual Reports ran to circa 350 pages each; we are “cutting out” unnecessary and meaningless data but nevertheless, each of these Reports are currently running at around circa 262 pages each. And that is a total of 14 Reports.
It is an understatement to say that is a lot of work.
To summarize, we will not take short cuts, abbreviate nor lower our disclosure standards whatsoever. We decided rather (if necessary) take an extra business day or two; but be right and furnish our shareholders and investors will full and accurate disclosure in enormous depth complete with very detailed notes.
P.S. Truthfully, the FIRST Filing being the Year Ended September 30, 2015, serves as the “Template” for all of the subsequent Filings as it details all transactions from October 1, 2013 to April 30, 2019 (That is an awful lot of disclosure and accompanying notes for a period of nearly 6 years). The subsequent Filings will contain that same data. That puts us in 100% compliance and very much within in the spirit of the revised OTC Markets Disclosure Rules.
Yes, I obviously anticipate a lot of further Press Releases, transactions, etc. Our SOLE concern is to complete and upload all of the outstanding Quarterly and Annual Reports. We have a lot waiting our consummation and due diligence reviews.
Kind Regards,
Ron Lowenthal
GNCP...thanks for sharing. (Preaching to the choir, brother...amen!)
GNCP...Thanks TFF!!
GNCP...No CANT, No NSS, No coincidence!!
GNCP...Tweet
GNCC Capital, Inc.
@gncccapital
10m10 minutes ago
GNCC Capital, Inc. (OTC: GNCP) confirms subsequent event filings and the Quarter Ended March 31, 2019 filed on Sunday May 19, 2019 as promised to shareholders. Attorney Letter required to be PINK CURRENT was promised by Monday May 20, 2019 by the Company's Counsel of record.
GNCP...Second reply from Ron
Sir,
Material events are filed on the OTCIQ system of the OTC Markets. A Press Release is not required.
GNCP...Clarification update from Ron.
Sir,
No, a Press Release in the Regulatory Filings is not required.
Thanks for your kind words, it has been a long road that we have travelled!
GNCP...Appears to me the bid has now exceeded the ask-illusion
Bid Size $0.0002 x 169,466,500 & Ask Size $0.0003 x 134,906,700
GNCP...IMO the timing is not a coincidence. We are partially and inadvertently the eyes and ears of these groups which is why I always take great pleasure in posting positive news!
GNCP...I'm in buddy! Adding to the buck a share club at market open this morning.
GNCP...I believe that Ron is being instructed to delay all GNCP/BioCann Pharma news updates as long as possible. As of March 1st I feel that Instadose is truly running 100% of the shot calls with GNCP/BioCann Pharma. Instadose is keeping BioCann Pharma nearly invisible to the public eye. Even Ron eluded to the NUMEROUS NDAs that he and Ted were required to sign before discussing any dealings with Instadose. Even when reviewing all of the latest updates on the Instadose Pharma website, there is still minimal info provided on Colombia with zero mention of BioCann Pharma...noting to call Instadose for more information on Colombia. After all, GNCP didnt pick the name BioCann Pharma, Instadose Pharma developed that name and it certainly targets the industry they're planning to dominate. Investors currently sitting on the sidelines may want to consider this information and determine whether it's worth the risk / reward of taking a position before all starts to reveal itself and the curtain finally drops. All in my opinion. Happy Friday!!
GNCP...the good news is that GTSM "can't" turn to bankruptcy as their exit plan.
GNCP...Do you think this was a loophole to start their megabillions of NSS covering under $0.01?
GNCP...my thoughts, as well. TGIPRF? Thank God It's Press Release Friday?? Or does he hammer everything out on Sunday??? Stay tuned!!